Hepatitis C Market Size, Share, Trends, Growth Outlook

Hepatitis C Market is estimated to increase at a Compounded Annual Growth Rate of 12.8% CAGR over the forecast period from 2024 to 2030

The Hepatitis C Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Diagnosis (Liver Biopsy, Blood Tests), By Treatment (Antiviral Drugs, Immune Modulator Drugs, Others), By End-User (Hospitals and Clinics, Diagnostic Laboratory, Others).

An Introduction to Hepatitis C Market in 2024

In 2024, the market for hepatitis C (HCV) therapies continues to undergo transformative changes, driven by advancements in antiviral agents, diagnostic technologies, and public health initiatives aimed at eliminating the disease. Hepatitis C remains a significant global health challenge, with millions of individuals affected by chronic HCV infection and its associated complications, including liver cirrhosis and hepatocellular carcinoma. However, the landscape of HCV treatment has been revolutionized by the development of direct-acting antiviral (DAA) agents, which offer high cure rates, shorter treatment durations, and improved tolerability compared to traditional interferon-based regimens. Furthermore, the integration of point-of-care diagnostics and screening programs is facilitating early detection and linkage to care, crucial steps in reducing HCV transmission and disease burden. With a growing emphasis on HCV elimination goals set forth by global health organizations, the hepatitis C market is witnessing increased investment in research, development, and access initiatives, paving the way for a future free of HCV-related morbidity and mortality.

Market Trend: Increased Adoption of Direct-Acting Antiviral (DAA) Therapies

A significant trend in the hepatitis C market is the increased adoption of direct-acting antiviral (DAA) therapies. These highly effective and well-tolerated oral medications have revolutionized the treatment landscape for hepatitis C by offering high cure rates, shorter treatment durations, and fewer side effects compared to traditional interferon-based therapies. As a result, there has been a shift towards DAA therapies as the standard of care for hepatitis C treatment, driving market growth and improving outcomes for patients.

Market Driver: Growing Awareness and Screening Initiatives

The primary drivers propelling the hepatitis C market are the growing awareness of the disease and increased screening initiatives worldwide. Efforts to raise awareness about hepatitis C risk factors, transmission routes, and the importance of testing have led to a greater number of individuals being diagnosed with the virus. Moreover, targeted screening programs in high-risk populations, such as injection drug users, baby boomers, and those with a history of blood transfusions, have contributed to early detection and treatment initiation. This heightened awareness and increased screening drive the demand for hepatitis C diagnostic tests, medications, and healthcare services, fueling market growth.

Market Opportunity: Expansion of Treatment Access and Elimination Efforts

An attractive opportunity within the hepatitis C market is the expansion of treatment access and elimination efforts. Despite significant advancements in hepatitis C treatment, access to care remains a challenge in many regions due to factors such as limited healthcare infrastructure, high treatment costs, and stigma associated with the disease. By implementing strategies to improve access to affordable diagnostics and medications, scaling up treatment programs, and implementing prevention initiatives, stakeholders can work towards the global goal of eliminating hepatitis C as a public health threat by 2030, as outlined by the World Health Organization. This presents an opportunity to not only improve patient outcomes but also reduce the burden of hepatitis C-related morbidity and mortality on healthcare systems worldwide.

Hepatitis C Market Share Analysis: Antiviral Drugs

In the Hepatitis C Market, the segment experiencing the fastest growth is Antiviral Drugs. Antiviral drugs are the cornerstone of hepatitis C treatment, aiming to suppress viral replication and reduce the risk of disease progression, liver cirrhosis, and hepatocellular carcinoma. With the advent of direct-acting antiviral (DAA) therapies, which offer high cure rates and fewer side effects compared to traditional interferon-based regimens, there has been a paradigm shift in the management of hepatitis C. These highly effective and well-tolerated oral medications have revolutionized the treatment landscape, making hepatitis C a curable disease for the majority of patients. As a result, there is a growing demand for antiviral drugs among healthcare providers and patients alike. Hospitals and clinics, along with diagnostic laboratories, are key end-users driving the uptake of antiviral drugs as they play a central role in the diagnosis, treatment, and monitoring of hepatitis C patients. With ongoing research and development efforts aimed at further improving the efficacy and accessibility of antiviral therapies, this segment is poised for significant growth in the hepatitis C market.

Hepatitis C Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbVie Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company, Cipla Inc, Daiichi Sankyo Company Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Ltd

Hepatitis C Market Segmentation

By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Hepatitis C Market Companies

AbbVie Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
Cipla Inc
Daiichi Sankyo Company Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Takeda Pharmaceutical Company Ltd

Reasons to Buy the Hepatitis C Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Hepatitis C Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Hepatitis C Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Hepatitis C Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Hepatitis C Market Size Outlook, $ Million, 2021 to 2030
3.2 Hepatitis C Market Outlook by Type, $ Million, 2021 to 2030
3.3 Hepatitis C Market Outlook by Product, $ Million, 2021 to 2030
3.4 Hepatitis C Market Outlook by Application, $ Million, 2021 to 2030
3.5 Hepatitis C Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Hepatitis C Industry
4.2 Key Market Trends in Hepatitis C Industry
4.3 Potential Opportunities in Hepatitis C Industry
4.4 Key Challenges in Hepatitis C Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Hepatitis C Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Hepatitis C Market Outlook by Segments
7.1 Hepatitis C Market Outlook by Segments, $ Million, 2021- 2030
By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others

8 North America Hepatitis C Market Analysis and Outlook To 2030
8.1 Introduction to North America Hepatitis C Markets in 2024
8.2 North America Hepatitis C Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Hepatitis C Market size Outlook by Segments, 2021-2030
By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others

9 Europe Hepatitis C Market Analysis and Outlook To 2030
9.1 Introduction to Europe Hepatitis C Markets in 2024
9.2 Europe Hepatitis C Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Hepatitis C Market Size Outlook by Segments, 2021-2030
By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others

10 Asia Pacific Hepatitis C Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Hepatitis C Markets in 2024
10.2 Asia Pacific Hepatitis C Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Hepatitis C Market size Outlook by Segments, 2021-2030
By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others

11 South America Hepatitis C Market Analysis and Outlook To 2030
11.1 Introduction to South America Hepatitis C Markets in 2024
11.2 South America Hepatitis C Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Hepatitis C Market size Outlook by Segments, 2021-2030
By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others
12 Middle East and Africa Hepatitis C Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Hepatitis C Markets in 2024
12.2 Middle East and Africa Hepatitis C Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Hepatitis C Market size Outlook by Segments, 2021-2030
By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
Cipla Inc
Daiichi Sankyo Company Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Takeda Pharmaceutical Company Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Diagnosis
Liver Biopsy
Blood Tests
By Treatment
Antiviral Drugs
Immune Modulator Drugs
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratory
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)